1. Introduction {#sec1-marinedrugs-14-00122}
===============

Epithiodiketopiperazines with 1,2-oxazadecaline moiety are rare in nature. To date, only eleven such compounds have been reported \[[@B1-marinedrugs-14-00122],[@B2-marinedrugs-14-00122],[@B3-marinedrugs-14-00122],[@B4-marinedrugs-14-00122]\]. Structural differences in compounds of this class consist in *N*-methylation, C-4--C-5-epoxidation \[[@B5-marinedrugs-14-00122],[@B6-marinedrugs-14-00122]\] and substituent at C-5. In addition, first mono- and trithioderivatives have recently been reported \[[@B3-marinedrugs-14-00122],[@B4-marinedrugs-14-00122]\]. The fungi of genus *Trichoderma* were producers of most of these alkaloids. However, pretrichodermamide A has also been reported to be synthesized by *Aspergillus* sp. \[[@B7-marinedrugs-14-00122]\], while *N*-methylated compounds methylgliovirin (the first described compound from this class) \[[@B5-marinedrugs-14-00122]\], *N*-methylpretrichodermamide B (adametizine A) \[[@B8-marinedrugs-14-00122],[@B9-marinedrugs-14-00122]\], and pretrichodermamide C (adametizine B) \[[@B8-marinedrugs-14-00122],[@B9-marinedrugs-14-00122]\] have only been isolated from *Penicillium* species. Many oxazadecaline thiodiketopiperazines have been reported and patented as antibiotics, and chloroderivatives have shown cytotoxic activity against murine lymphoma and Jurkat cells with IC~50~ of 2--5 µM \[[@B2-marinedrugs-14-00122],[@B8-marinedrugs-14-00122],[@B9-marinedrugs-14-00122],[@B10-marinedrugs-14-00122]\]. During our ongoing search for structurally novel and bioactive metabolites from marine-derived fungi, we investigated the fungus *Penicillium* sp. KMM 4672 isolated from Vietnamese brown alga *Padina* sp. A chemical study resulted in the isolation and identification of three new 1,2-oxazadecaline epidithiodiketopiperazines pretrichodermamides D--F (**1**--**3**), together with the known pretrichodermamide C (**4**) and *N*-methylpretrichodermamide B (**5**) ([Figure 1](#marinedrugs-14-00122-f001){ref-type="fig"}). Herein, we report the isolation, structure elucidation, and biological assay results of the new compounds **1**--**3** produced by the marine fungus *Penicillium* sp.

2. Results {#sec2-marinedrugs-14-00122}
==========

The EtOAc extract of the culture of the fungus was suspended in H~2~O--EtOH (4:1) and successively partitioned with hexane, EtOAc, and *n-*BuOH. The EtOAc portion was subjected to column chromatography over silica gel and by HPLC to yield individual compounds **1**--**5** as white powders.

The molecular formula of compound **1** was determined to be C~21~H~24~N~2~O~9~S~2~ from a HRESIMS peak at *m/z* 511.0857 \[M − H\]^−^ and was in accordance with ^13^C NMR data. A thorough analysis of the ^1^H and ^13^C NMR data ([Table 1](#marinedrugs-14-00122-t001){ref-type="table"}) of **1** with DEPT and HSQC techniques revealed the presence of two methoxyls, one N-methyl, one methylene, four sp^2^-methines, and five sp^3^-methines together with two sp^3^-quaternary carbons. The remaining functionalities, corresponding to the carbon signals at δ~C~ 165.4 (C), 164.2 (C), 153.0 (C), 147.6 (C), 135.9 (C), and 116.3 (С), suggested the presence of two amide carbonyl carbons, three oxygenated, and one C-substituted sp^2^-carbons.

A direct comparison of ^1^H and ^13^C NMR spectra of **1** ([Table 1](#marinedrugs-14-00122-t001){ref-type="table"}) with those of pretrichodermamide C (**4**) \[[@B8-marinedrugs-14-00122]\] ([S21--S22, Supplementary data](#app1-marinedrugs-14-00122){ref-type="app"}) showed similarities including signals of two methoxyls (δ~H~ 3.68, 3.78; δ~C~ 55.7, 60.2), *N*-methyl (δ~H~ 2.96; δ~C~ 32.6), one phenolic hydroxyl group (δ~H~ 9.43), two aromatic methine (δ~H~ 6.55, 7.32; δ~C~ 103.3, 122.6), and two amide carbonyls (δ~C~ 164.2, 165.4), suggesting that **1** has a framework similar to that of 4.

The HMBC correlations from both H-3 (δ~H~ 2.17, 2.33) to C-4 (δ~C~ 66.9), C-5 (δ~C~ 133.8), and C-9 (δ~C~ 81.9), from 4-OH (δ~H~ 5.26) to C-3 (δ~C~ 38.4), C-4, C-5, and C-9, from H-9 (δ~H~ 4.12) to C-8 (δ~C~ 66.2), and from H-7 (δ~H~ 4.03) to C-5, C-6 (δ~C~ 127.4), and C-8 established the cyclohexene ring with a C-5--C-6 double bond placement. The location of secondary hydroxyl groups at C-7 and C-8 was proven by HMBC correlations from 7-OH (δ~H~ 4.89) to C-7 and from 8-OH (δ~H~ 4.35) to C-8. The planar structure of **1** was thus elucidated.

Esterification of the C-7 and C-9′ hydroxy moieties of **1** with (*R*)- and (*S*)-MTPA chloride afforded the (*S*)- and (*R*)-bis-MTPA-esters, respectively. The observed chemical shift differences Δδ (δ~S~ − δ~R~) ([Figure 2](#marinedrugs-14-00122-f002){ref-type="fig"}) indicated 7*R* configuration \[[@B11-marinedrugs-14-00122]\]. The absolute configurations of the remaining stereocentres in cyclohexene ring were established as 4*S*, 8*R*, 9*S*, the same as in adametizine B (pretrichodermamide C) and adametizine A (*N*-methylpretrichodermamide B) ([Figure 3](#marinedrugs-14-00122-f003){ref-type="fig"}) based on the ROESY-correlations 7-OH with H-9, and H-9 with 4-OH and 8-OH, together with the coupling constants ^3^*J*~H8-H9~ (9.4 Hz) and ^3^*J*~H7-H8~ (4.6 Hz), which were in accordance with calculated dihedral angles (177° and 46°, respectively). The absolute configurations at C-2, C-2′, and C-3′ were assigned to be the same as known adametizine A and adametizine B on the basis of the similarity of C-2, C-2′, and C-3′ chemical shifts for these biogenetically related compounds \[[@B9-marinedrugs-14-00122]\]. Compound **1** was named pretrichodermamide D.

The molecular formula of compound **2** was determined as C~21~H~24~N~2~O~9~S~2~, the same as **1**, by a HRESIMS peak at *m/z* 511.0869 \[M − H\]^−^ and by ^13^C NMR analysis. The general features of the ^1^H and ^13^C NMR spectra ([Table 1](#marinedrugs-14-00122-t001){ref-type="table"}) of **2** resembled those of **1** with the exception of the proton and carbon signals at C-7 and C-8. The HMBC correlations from H-7 (δ~H~ 3.96) to C-6 (δ~C~ 129.7) and C-8 (δ~C~ 71.0), from H-9 (δ~H~ 3.83) to C-4 (δ~C~ 67.0) and C-8, and from 4-OH (δ~H~ 5.29) to C-3 (δ~C~ 39.0), C-5 (δ~C~ 131.8), and C-9 (δ~C~ 83.4) proved that the planar structure of **2** was identical with pretrichodermamide D (**1**). The vicinal coupling constant *J*~H7-H8~ (7.7 Hz) and *J*~H8-H9~ (10.7 Hz) according to Karplus equation (calculated dihedral angles are 168° and 174°, respectively) indicated the axial stereolocations of H-7, H-8 (δ~H~ 3.56), and H-9. These relative configurations were additionally proved by ROESY's ([Figure 3](#marinedrugs-14-00122-f003){ref-type="fig"}) H-7 with 8-OH (δ~H~ 4.64) and H-9. The absolute stereoconfigurations of **2** were assigned as for pretrichodermamide D (**1**) according to biogenetic considerations. Thus, compound **2** was determined as the C-7 epimer of pretrichodermamide D and named pretrichodermamide E.

The molecular formula of compound **3** was determined as C~21~H~24~N~2~O~9~S~2~ (the same as **1** and **2**) on the basis of HRESIMS and ^13^C NMR spectra. The NMR data for this compound were very similar to those obtained for pretrichodermamide C (**4**) with the exception of proton and carbon signals at C-3, C-4, C-5, C-6, and C-9. The HMBC correlations from H-5 (δ~H~ 3.69) to C-3 (δ~C~ 35.6), C-4 (δ~C~ 67.4), C-6 (δ~C~ 126.9), and C-7 (δ~C~ 131.2), from H-8 (δ~H~ 4.16) to C-7 and C-9 (δ~C~ 83.5), and from H-9 (δ~H~ 3.97) to C-4 and C-8 (δ~C~ 64.6) established a planar structure of the cyclohexene ring with a double bond between C-6 and C-7. The mutual ROESY correlations ([Figure 3](#marinedrugs-14-00122-f003){ref-type="fig"}) from H-9 to 4-OH (δ~H~ 4.96), 5-OH (δ~H~ 5.19), and 8-OH (δ~H~ 5.15) showed α-orientation of 5-OH and detected **3** as the С-5-epimer of pretrichodermamide C (**4**). The relative configurations of the 1,2-oxazadecaline fragment were additionally suggested by a W-type coupling constant between H-9 (δ~H~ 3.97, dd, 7.3, 1.5) and H-3β (δ~H~ 2.06, dd, 15.4, 1.5). The absolute configurations in compound **3** were proposed based on biogenetic relationships with compounds **1**, **2**, **4**, and **5**. Compound **3** was named pretrichodermamide F.

Besides the new pretrichodermamides D--F (**1**--**3**), the known pretrichodermamide C (**4**) and *N*-methylpretrichodermamide B (**5**) were also isolated from this fungus. For the first time these compounds were found in Egyptian hyper saline lake fungus *Penicillium* sp. \[[@B8-marinedrugs-14-00122]\] and were later isolated from sponge-derived *Penicillium adametzioides* and published as new adametizines A and B, respectively. The absolute stereochemistry for adametizines were determined based on X-ray and ECD data \[[@B9-marinedrugs-14-00122]\]. The structures of **4** and **5** were established on the basis of 1D and 2D NMR data and high resolution ESIMS analysis ([Supplementary data S20--S26](#app1-marinedrugs-14-00122){ref-type="app"}). The absolute structures of compounds **4** and **5** were determined the same as for adametizines B and A, respectively, based on identity of their ECD spectra.

In a next step, we investigated the effects of compounds **1**--**5** on viability and the apoptosis induction of human prostate cancer cells. It should be noted that, in a recently published study, *N*-methylpretrichodermamide B did not show any cytotoxic effect against a number of different cancer cells up to 10 µM \[[@B9-marinedrugs-14-00122]\]. MTT assays revealed *N*-methylpretrichodermamide B (**5**) to be highly cytotoxic in 22Rv1, PC-3, and LNCaP cells with IC~50~ 0.51, 5.11, and 1.76 µM, respectively, while revealed IC~50~s of 0.013, 0.015, and 0.004 µM were determined for docetaxel (positive control). Remarkably, **5** induces apoptosis in human prostate cancer 22Rv1 cells (31.3% ± 8.2% apoptosis after treatment with 1 µM for 48 h), which are highly resistant to androgen receptor (AR)-targeted therapies due to a loss of the ligand-binding domain of the AR receptor \[[@B12-marinedrugs-14-00122]\]. Сompounds **1**--**4** did not exhibit cytotoxic activity against human prostate cancer cells at concentrations up to 100 µM. No significant effect on cell cycle progression was observed for any of the compounds at concentrations up to 100 µM. 22Rv1 cells are known to be resistant to the hormone therapy due to the presence of androgen receptor splice variant AR-V7, while LNCaP cells bearing *w*/*t* AR are sensitive to the hormone deprivation \[[@B12-marinedrugs-14-00122]\]. Remarkably, **5** was mostly active in AR-V7-positive 22Rv1 cells with IC~50~ at nanomolar concentrations (MTT test). In addition, the effect of compounds **1**--**5** was tested on non-malignant murine cells (splenocytes and erythrocytes). *N*-methylpretrichodermamide B (**5**) did not show hemolitic activity up to 100 µM and was cytotoxic for splenocytes only at high doses (ED~50~ 62.1 µM).

3. Materials and Methods {#sec3-marinedrugs-14-00122}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-14-00122}
------------------------------------

Optical rotations were measured on a Perkin-Elmer 343 polarimeter (Perkin Elmer, Waltham, MA, USA). UV spectra were recorded on a Specord UV VIS spectrometer (Carl Zeiss, Jena, Germany) in MeOH. IR spectra were determined on a Specord M 82 (Carl Zeiss, Jena, Germany) in CHCI~3~. NMR spectra were recorded in DMSO-d~6~ on a Bruker DPX-500 (Bruker BioSpin GmbH, Rheinstetten, Germany) (500.13/125.77 MHz) and Bruker DRX-700 (Bruker BioSpin GmbH, Rheinstetten, Germany) (700.00/176.04 MHz) spectrometer, using TMS as an internal standard. HRESIMS spectra were measured on an Agilent 6510 Q-TOF LC mass spectrometer (Agilent Technologies, Santa Clara, CA, USA).

Low pressure liquid column chromatography was performed using silica gel (50/100 μm, Imid, Russia). Plates (4.5 × 6.0 cm) precoated with silica gel (5--17 μm, Imid) were used for thin layer chromatography. Preparative HPLC was carried out on a Shimadzu LC-20 chromatograph (Shimadzu USA Manufacturing, Canby, OR, USA) using a YMC ODS-AM (YMC Co., Ishikawa, Japan) (5 µm, 10 × 250 mm) and YMC SIL (YMC Co., Ishikawa, Japan) (5 µm, 10 × 250 mm) columns with an Shimadzu RID-20A refractometer (Shimadzu Corporation, Kyoto, Japan).

The energy-minimized structure models for **1**--**3** have been calculated based on crystallographic data (CCDC 1040973) for adametizine A (*N*-methylpretrichodermamide, compound **5**) \[[@B9-marinedrugs-14-00122]\] by the MM2 force field calculation method using ChemBio3D Ultra 12.0, CambridgeSoft Corporation (Cambridge, MA, USA).

3.2. Fungal Strain {#sec3dot2-marinedrugs-14-00122}
------------------

The strain was isolated from brown algae *Padina* sp. (South China Sea, Vietnam) by the plating method using malt extract agar and identified on the basis of morphological and molecular features. For DNA extraction, the culture was grown on malt extract agar under 25 °C for 7 d. DNA extraction was performed by HiPurATM Plant DNA Isolation kit (CTAB Method) (HiMedia Laboratories Pvt. Ltd., Mumbai, India) according to the manufacturer′s instructions. Fragments containing the ITS regions were amplified using primers ITS1 and ITS4 \[[@B13-marinedrugs-14-00122]\]. Amplification of the partial calmodulin gene was performed using Cmd5 and Cmd6 primers \[[@B14-marinedrugs-14-00122]\]. The newly obtained sequences were checked visually and compared to available sequences of GenBank by using BLAST-n. According to BLAST analysis of the ITS1-5.8S-ITS2 and partial calmodulin datasets, the strain *Penicillium* sp. KMM 4672 is related to *P. citrinum*-group and displays the most similarity with *P. steckii* (99% and 97%, respectively). The sequences were deposited in GenBank nucleotide sequence database under KU 695807 and KU 695808. The strain was deposited in the Collection of Marine Microorganisms under the code KMM 4672.

3.3. Cultivation of Fungus {#sec3dot3-marinedrugs-14-00122}
--------------------------

The fungus was grown stationary at 22 °С for three weeks in 60 × 500 mL Erlenmeyer flasks, each containing 60 g of the solid nutrient medium of the following composition: rice (20.0 g), yeast extract (20.0 mg), KH~2~PO~4~ (10 mg), and natural sea water (40 mL).

3.4. Extraction and Isolation {#sec3dot4-marinedrugs-14-00122}
-----------------------------

The fungal mycelia with the medium were extracted for 24 h with 12 L of EtOAc. Evaporation of the solvent under reduced pressure yielded a brown oil (9.2 g), to which 250 mL of H~2~O--EtOH (4:1) was added, and the combination was thoroughly mixed to yield a suspension. It was extracted successively with hexane (150 mL × 2), EtOAc (150 mL × 2) and *n-*BuOH (150 mL × 2). The EtOAc fraction was concentrated in vacuo to give a residue (6.0 g), which was separated on a silica gel column (30 × 3cm) eluted with a hexane-EtOAc gradient (1:0--0:1). The hexane-EtOAc fraction PS-101-64 (65:35, 210 mg) was purified by RP HPLC on a YMC ODS-AM column eluting with MeOH--H~2~O (65:35) to yield **5** (170 mg). The hexane-EtOAc fraction PS-101-87 (50:50, 73 mg) was separated by RP HPLC on a YMC ODS-AM column eluting with MeOH--H~2~O (65:35) to yield the **4** (16 mg), **1** (4.6 mg) and PS-103-4 fractions (7.8 mg). The PS-103-4 fraction was purified by HPLC on a YMC Sil column eluting with CHCl~3~--MeOH (95:5) to yield **2** (3.4 mg) and **3** (3.2 mg).

Pretrichodermamide D (**1**): white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20}$ −205 (*c* 0.17, MeOH); UV (MeOH) λ~max~ (log ε) 205 (4.54) nm; ECD (0.17 mM, MeOH) λ~max~ (Δε) 218 (−20.33), 258 (−6.98), 301 (+0.83) nm; ^1^H and ^13^C NMR data, see [Table 1](#marinedrugs-14-00122-t001){ref-type="table"}, [Supplementary data S1--S6](#app1-marinedrugs-14-00122){ref-type="app"}; HRESIMS *m/z* 511.0859 \[M − H\]^−^ (calcd for C~21~H~23~N~2~O~9~S~2~, 511.0850).

Pretrichodermamide E (**2**): white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20}$ −85 (*c* 0.4, MeOH); UV (MeOH) λ~max~ (log ε) 205 (4.51) nm; ECD (0.21 mM, MeOH) λ~max~ (Δε) 218 (−17.64), 258 (−6.04), 300 (+0.80) nm; IR (CHCl~3~) *ν*~max~ 3514, 3000, 2842, 1694, 1617, 1509, 1466, 1346, 1274, 1097, 1056, 1029 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-14-00122-t001){ref-type="table"}, [Supplementary data S7--S13](#app1-marinedrugs-14-00122){ref-type="app"}; HRESIMS *m/z* 511.0869 \[M − H\]^−^ (calcd for C~21~H~23~N~2~O~9~S~2~, 511.0850).

Pretrichodermamide F (**3**): white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20}$ −114 (*c* 0.4, MeOH); UV (MeOH) λ~max~ (log ε) 206 (4.45) nm; ECD (0.17 mM, MeOH) λ~max~ (Δε) 217 (−23.27), 260 (−6.64), 301 (+0.49) nm; IR (CHCl~3~) *ν*~max~ 3515, 3001, 2842, 1692, 1617, 1509, 1466, 1347, 1277, 1098, 1054, 1036 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-14-00122-t001){ref-type="table"}, [Supplementary data S14--S20](#app1-marinedrugs-14-00122){ref-type="app"}; HRESIMS *m/z* 535.0815 \[M + Na\]^+^ (calcd for C~21~H~24~N~2~O~9~S~2~Na, 535.0815).

Pretrichodermamide C (**4**): white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20}$ −166.9 (*c* 0.09, MeOH) \[lit. ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20}$ −167.0 (*c* 0.12, MeOH)\] \[[@B8-marinedrugs-14-00122]\]; UV (MeOH) λ~max~ (log ε) 206 (4.34) nm; ECD (0.20 mM, MeOH) λ~max~ (Δε) 217 (−27.17), 262 (−7.03), 303 (+0.69) nm; ^1^H and ^13^C NMR data, see [Supplementary data S21--S22](#app1-marinedrugs-14-00122){ref-type="app"}; HRESIMS *m/z* 535.0830 \[M + Na\]^+^ (calcd for C~21~H~24~N~2~O~9~S~2~Na, 535.0815).

*N*-methylpretrichodermamide B (**5**): white powder; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20}$ −232.0 (*c* 0.14, MeOH) \[lit. ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{20}$ −102.0 (*c* 0.07, MeOH)\] \[[@B8-marinedrugs-14-00122]\]; UV (MeOH) λ~max~ (log ε) 205 (4.56) nm; ECD (0.32 mM, MeOH) λ~max~ (Δε) 217 (−42.10), 262 (−9.18), 303 (+0.87) nm; ^1^H and ^13^C NMR data, see [Supplementary data S23--S26](#app1-marinedrugs-14-00122){ref-type="app"}; HRESIMS *m/z* 553.0479 \[M + Na\]^+^ (calcd for C~21~H~23~N~2~O~8~S~2~ClNa, 553.0477).

3.5. Preparation of (S)-MTPA and (R)-MTPA Esters of Pretrichodermamide D (**1**) {#sec3dot5-marinedrugs-14-00122}
--------------------------------------------------------------------------------

4-dimethylaminopyridine (a few crystals) and (*R*)-MTPA-Cl (5 μL) was added to a solution of the pretrichodermamide D (1.8 mg) in pyridine at room temperature and stirred for 4 h. After evaporation of the solvent, the residue was passed through a silica gel column (20% EtOAc-hexane) to afford the (*S*)-MTPA ester (1.0 mg). The (*R*)-MTPA ester (1.2 mg) was prepared in a similar manner using (*S*)-MTPA-Cl.

(*S*)-MTPA ester of **1**: ^1^H NMR (DMSO-*d*~6~, 500.13 MHz) δ: 7.16 (1H, d, *J* = 9.4 Hz, H-6′), 6.04 (1H, s, 4-OH), 5.93 (1H, d, *J* = 9.8 Hz, H-5), 5.80 (1H, dd, *J* = 9.8; 5.2 Hz, H-6), 5.73 (1H, t, *J* = 4.9, H-7), 4.67 (1H, d, *J* = 3.7, 8-OH), 4.30 (1H, dt, *J* = 11.0; 4.5 Hz, H-8), 3.89 (3H, s, 8′-OMe), 3.68 (3H, s, 7′-OMe), 3.68 (3H, s, OMe), 3.55 (3H, s, OMe), 2.90 (3H, s, Me-10′), 2.47 (1H, d, *J* = 15.3 Hz, H~2~-3), 2.38 (1H, d, *J* = 15.3 Hz, H~2~-3), 7.45--7.75 (11H, m, 2Ph, H-5′). The signals of H-2′ and H-3′ overlapped with solvent signals. HRESIMS *m/z* 979.1438 \[M + Cl\]^--^ (calcd for C~41~H~38~N~2~O~13~S~2~F~6~Cl, 979.1414).

(*R*)-MTPA ester of **1**: ^1^H NMR (DMSO-d~6~, 500.13 MHz) δ: 7.66 (1H, d, *J* = 8.9 Hz, H-5′), 7.17 (1H, d, *J* = 8.9 Hz, H-6′), 5.54 (1H, s, 4-OH), 5.85 (1H, d, *J* = 9.7 Hz, H-5), 5.64 (1H, dd, *J* = 9.7; 5.0 Hz, H-6), 5.65 (1H, t, *J* = 5.0, H-7), 5.27 (1H, d, *J* = 5.0, 8-OH), 4.15 (1H, dt, *J* = 10.3; 5.0 Hz, H-8), 3.89 (3H, s, 8′-OMe), 3.73 (3H, s, 7′-OMe), 3.72 (3H, s, OMe), 3.59 (3H, s, OMe), 2.28 (1H, d, *J* = 15.3 Hz, H~2~-3), 2.21 (1H, d, *J* = 15.3 Hz, H~2~-3), 7.40--7.68 (11H, m, 2Ph). The signals of H-2′, H-3′, and Me-10′ overlapped with solvent signals. HRESIMS *m/z* 979.1430 \[M + Cl\]^--^ (calcd for C~41~H~38~N~2~O~13~S~2~F~6~Cl, 979.1414).

3.6. Cell Culture {#sec3dot6-marinedrugs-14-00122}
-----------------

The human prostate cancer cells lines 22Rv1, PC-3, and LNCaP were purchased from ATCC. Cell lines were cultured according to the manufacturers instructions in 10% FBS/RPMI media (Invitrogen) with (for LNCaP) or without (for 22Rv1 and PC-3) 1 mM sodium pyruvate (Invitrogen). Cells were continuously kept in culture for a maximum of 3 months and were routinely inspected microscopically for stable phenotype and regularly checked for contamination with mycoplasma. Cell line authentication was performed by DSMZ (Braunschweig, Germany) using highly polymorphic short tandem repeat loci \[[@B15-marinedrugs-14-00122]\].

3.7. Cytotoxicity Assay {#sec3dot7-marinedrugs-14-00122}
-----------------------

The in vitro cytotoxicity of individual substances was evaluated using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, which was performed as previously described \[[@B16-marinedrugs-14-00122]\]. Cytotoxicity against CD-I mouse splenocytes was determined according to Freshney \[[@B17-marinedrugs-14-00122]\]. Docetaxel was used as a reference substance.

3.8. Cell Cycle and Apoptosis Induction Analysis {#sec3dot8-marinedrugs-14-00122}
------------------------------------------------

The cell cycle distribution was analyzed by flow cytometry using PI staining as described before with slight modifications \[[@B18-marinedrugs-14-00122]\]. In brief, cells were pre-incubated overnight in 6-well plates (2 × 10^5^ cells/well in 2 mL/well). The medium was changed to fresh medium containing different concentrations of the substances. After 48 h of treatment, cells were harvested with a trypsin-EDTA solution, fixed with 70% EtOH, stained, and analyzed by FACS. The results were quantitatively analyzed using Cell Quest Pro software (Version 5.2.1., BD Bioscience, Bedford, MA, USA). Cells appeared at sub-G1 peak were assumed as apoptotic.

3.9. Hemolytic Activity {#sec3dot9-marinedrugs-14-00122}
-----------------------

The hemolytic activity was evaluated using CD-I mouse erythrocytes as previously described \[[@B19-marinedrugs-14-00122],[@B20-marinedrugs-14-00122]\].

4. Conclusions {#sec4-marinedrugs-14-00122}
==============

Three new epidithiodiketopiperazines, named pretrichodermamides **D**--**F** (**1**--**3**) were isolated from the lipophilic extract of marine algae-derived fungus *Penicillium* sp. KMM 4672. Each new compound contains rare 1,2-oxazadecaline moieties \[[@B1-marinedrugs-14-00122]\]. Compounds **1** and **2** are the first isomers at oxazadecaline moiety among the related alkaloids. *N*-methylpretrichodermamide B (**5**), highly cytotoxic in 22Rv1 human prostate cancer cells, is resistant to androgen receptor-targeted therapies. At the same time, *N*-methylpretrichodermamide B was found to be cytotoxic for non-malignant cells (splenocytes and erythrocytes) only at high doses (ED50 62.1 and \>100 µM). Therefore, this compound may be a promising candidate for the therapy of human drug-resistant prostate cancer.

This study was supported by the Russian Science Foundation (grant No 14-14-00030).

^1^H, ^13^C, DEPT, COSY-45, HSQC, HMBC, and ROESY spectra of new compounds **1**--**3**, ^1^H, ^13^C, and DEPT spectra of compounds **4** and **5** are available online at [www.mdpi.com/1660-3397/14/6/122/s1](www.mdpi.com/1660-3397/14/6/122/s1).
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###### 

NMR spectroscopic data (DMSO-*d*~6~) for pretrichodermamides D--F (**1**--**3**).

  ------------------------------------------------------------------------------------------------------------------------------------------
  Position   1 ^a^         2 ^b^                       3 ^b^                                                    
  ---------- ------------- --------------------------- ------------- ---------------------------- ------------- ----------------------------
  1          165.4, C      \-                          165.5, C      \-                           165.4, C      \-

  2          68.0, C       \-                          67.7, C       \-                           69.1, C       \-

  3          38.4, CH~2~   α: 2.17, d (15.3)\          39.0, CH~2~   α: 2.22, d (15.7)\           35.6, CH~2~   α: 1.93, brd (15.5)\
                           β: 2.33, d (15.3)                         β: 2.27, d (15.5)                          β: 2.06, dd (15.4, 1.5)

  4          66.9, C       \-                          67.0, C       \-                           67.4, C       \-

  5          133.8, CH     5.56, d (10.1)              131.8, CH     5.54, dd (10.1, 2.2)         69.2, CH      3.69, d (5.5)

  6          127.4, CH     5.60, dd (10.0, 4.4)        129.7, CH     5.43, dd (10.2, 2.2)         126.9, CH     5.69, ddd (10.0, 5.1, 2.3)

  7          65.8, CH      4.03, q (4.5)               72.2, CH      3.96, tt (7.7, 2.2)          131.2, CH     5.56, dd (9.9, 2.5)

  8          66.2, CH      3.74, ddd (9.4, 6.6, 4.6)   71.0, CH      3.56, ddd (10.7, 7.7, 5.7)   64.6, CH      4.16, m

  9          81.9, CH      4.12, d (9.4)               83.4, CH      3.83, d (10.7)               83.5, CH      3.97, dd (7.1, 1.5)

  1′         164.2, C      \-                          164.4, C      \-                           163.8, C      \-

  2′         66.0, CH      4.56, d (2.6)               65.7, CH      4.57, d (2.6)                65.4, CH      4.57, d (2.6)

  3′         41.4, CH      4.55, d (2.5)               41.5, CH      4.58, d (2.5)                41.0, CH      4.59, d (2.5)

  4′         116.3, C      \-                          116.3, C      \-                           116.3, C      \-

  5′         122.6, CH     7.32, d (8.8)               122.6, CH     7.32, d (8.8)                122.7, CH     7.35, d (8.8)

  6′         103.3, CH     6.55, d (8.8)               103.3, CH     6.55, d (8.8)                103.2, CH     6.54, d (8.8)

  7′         153.0, C      \-                          153.0, C      \-                           152.8, C      \-

  8′         135.9, C      \-                          135.9, C      \-                           135.8, C      \-

  9′         147.6, C      \-                          147.5, C      \-                           147.5, C      \-

  10′        32.6, CH~3~   2.96, s                     32.6, CH~3~   2.96, s                      32.5, CH~3~   2.96, s

  7′-OMe     55.7, CH~3~   3.78, s                     55.6, CH~3~   3.78, s                      55.6, CH~3~   3.78, s

  8′-OMe     60.2, CH~3~   3.68, s                     60.2, CH~3~   3.68, s                      60.2, CH~3~   3.68, s

  9′-OH      \-            9.43, s                     \-            9.42, s                      \-            9.38, s

  4-OH       \-            5.26, s                     \-            5.29, s                      \-            4.96, brs

  5-OH       \-            \-                          \-            \-                           \-            5.19, d (5.6)

  7-OH       \-            4.89, d (5.4)               \-            5.02, d (6.9)                \-            

  8-OH       \-            4.35, d (6.6)               \-            4.64, d (5.7)                \-            5.15, d (6.7)
  ------------------------------------------------------------------------------------------------------------------------------------------

^a^ ^1^H NMR and ^13^C NMR spectroscopic data were measured at 500.13 MHz and 125.77 MHz, respectively; ^b^ ^1^H NMR and ^13^C NMR spectroscopic data were measured at 700.00 MHz and 176.04 MHz, respectively.
